E
Eunice L. Kwak
Researcher at Harvard University
Publications - 148
Citations - 24080
Eunice L. Kwak is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & FOLFIRINOX. The author has an hindex of 49, co-authored 146 publications receiving 21705 citations.
Papers
More filters
Journal ArticleDOI
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak,Yung-Jue Bang,D. Ross Camidge,Alice T. Shaw,Benjamin Solomon,Robert G. Maki,Sai-Hong Ignatius Ou,Bruce J. Dezube,Pasi A. Jänne,Daniel B. Costa,Marileila Varella-Garcia,Woo-Ho Kim,Thomas J. Lynch,Panos Fidias,Hannah Stubbs,Jeffrey A. Engelman,Lecia V. Sequist,Weiwei Tan,Leena Gandhi,Mari Mino-Kenudson,Greg C. Wei,S. Martin Shreeve,Mark J. Ratain,Jeffrey Settleman,James G. Christensen,Daniel A. Haber,Keith D. Wilner,Ravi Salgia,Geoffrey I. Shapiro,Jeffrey W. Clark,A. John Iafrate +30 more
TL;DR: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw,Beow Y. Yeap,Mari Mino-Kenudson,Subba R. Digumarthy,Daniel B. Costa,Rebecca S. Heist,Benjamin Solomon,Hannah Stubbs,Sonal Admane,Ultan McDermott,Jeffrey Settleman,Susumu Kobayashi,Eugene J. Mark,Scott J. Rodig,Lucian R. Chirieac,Eunice L. Kwak,Thomas J. Lynch,A. John Iafrate +17 more
TL;DR: EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
Journal ArticleDOI
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon,Alice T. Shaw,Sai-Hong Ignatius Ou,Ryohei Katayama,Christine M. Lovly,Nerina T. McDonald,Pierre P. Massion,Christina Siwak-Tapp,Adriana Gonzalez,Rong Fang,Eugene J. Mark,Julie M. Batten,Haiquan Chen,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,David P. Carbone,Hongbin Ji,Jeffrey A. Engelman,Mari Mino-Kenudson,William Pao,A. John Iafrate +21 more
TL;DR: ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLCs, and crizotinib shows in vitro activity and early evidence of clinical activity in ROS1- rearrangedNSCLC.
Journal ArticleDOI
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge,Yung-Jue Bang,Eunice L. Kwak,A. John Iafrate,Marileila Varella-Garcia,Stephen B. Fox,Gregory J. Riely,Benjamin Solomon,Sai-Hong Ignatius Ou,Dong Wan Kim,Ravi Salgia,Panagiotis Fidias,Jeffrey A. Engelman,Leena Gandhi,Pasi A. Jänne,Daniel B. Costa,Geoffrey I. Shapiro,Patricia LoRusso,Katherine Ruffner,Patricia Stephenson,Yiyun Tang,Keith D. Wilner,Jeffrey W. Clark,Alice T. Shaw +23 more
TL;DR: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC and there seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.